Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation TCT 2024

TCT 665: Impact of Smoking on Outcomes in Patients With MINOCA

Presenter: Pawel Gasior

October 27, 2024

Presentation TCT 2022

TCT 38: Impact of Smoking on Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

Presenter: Marta Bujak

September 17, 2022

Presentation

Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI

April 15, 2020

Presentation ACC 2020

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

Presenter: Mark Eisenberg

March 30, 2020

Presentation TCT Abstracts Posters 2018

Impact of Smoking Status on Outcomes After Percutaneous Coronary Intervention

Presenter: Juan Wang

September 25, 2018

Presentation

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

Presenter: Grant Reed

February 28, 2016

Presentation TCT 2015

ASD After MitraClip: Is This the Smoking Gun?

Presenter: Stephan Baldus, Saibal Kar, Michael J. Lim

October 14, 2015

Presentation

Smoking Is Associated With Adverse Clinical Outcomes in Patients Undergoing PCI or CABG

Presenter: Y. J. Zhang

March 19, 2015

Presentation

Life Years Gained by Smoking Cessation After PCI

Presenter: S.P.M. de Boer

August 02, 2013

Presentation

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Presenter: Paul A. Gurbel

May 03, 2013

Presentation TCT 2013

Impact of Smoking on Outcomes of Acute Myocardial Infarction After Drug-Eluting Stent Implantation: The Smoker’s Paradox

Presenter: Yun-Kyeong Cho, Ji-Hyun Sohn, Hyun-Ok Cho, Hyoung-Seob Park, Hyuck-Jun Yoon, Hyungseop Kim, Chang-Wook Nam, Seung-Ho Hur, Yoon-Nyun Kim, Kwon-Bae Kim

January 31, 2013

Presentation

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

Presenter: Andrew L. Frelinger

January 15, 2013

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Presentation

Prior Smoking Status, Clinical Outcomes, and the Comparison of Ticagrelor with Clopidogrel in ACS

Presenter: Jan H. Cornel

August 02, 2012

Presentation

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Presenter: M. Ueno

March 19, 2012

Advertisement

TCT 665: Impact of Smoking on Outcomes in Patients With MINOCA

TCT 38: Impact of Smoking on Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

Impact of Smoking Status on Outcomes After Percutaneous Coronary Intervention

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

ASD After MitraClip: Is This the Smoking Gun?

Smoking Is Associated With Adverse Clinical Outcomes in Patients Undergoing PCI or CABG

Life Years Gained by Smoking Cessation After PCI

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Impact of Smoking on Outcomes of Acute Myocardial Infarction After Drug-Eluting Stent Implantation: The Smoker’s Paradox

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Prior Smoking Status, Clinical Outcomes, and the Comparison of Ticagrelor with Clopidogrel in ACS

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content